Cyclosporine Or Derivative Utilizing Patents (Class 514/20.5)
  • Publication number: 20130315981
    Abstract: The present invention is a method of increasing lipolysis in an adipose tissue of a mammal comprising delivering to macrophages at the adipose tissue of the mammal an effective amount of an agent which reduces the concentration of macrophages at the adipose tissue of the mammal, thereby increasing lipolysis in the adipose tissue of the mammal.
    Type: Application
    Filed: June 22, 2011
    Publication date: November 28, 2013
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Anthony W. Ferrante, JR., Aliki Kosteli
  • Publication number: 20130303462
    Abstract: The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain DPP-4 inhibitor, as well as to the use of a certain DPP-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.
    Type: Application
    Filed: May 13, 2013
    Publication date: November 14, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Thomas KLEIN, Maximilian von EYNATTEN, Berthold HOCHER, Michael MARK, Yuliya SHARKOVSKA
  • Patent number: 8575108
    Abstract: A composition comprising from about 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil having a specific gravity from 0.8 to 0.95 is disclosed herein.
    Type: Grant
    Filed: November 15, 2007
    Date of Patent: November 5, 2013
    Assignee: Allergan, Inc.
    Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
  • Patent number: 8568748
    Abstract: The present invention relates to a pharmaceutical formulation in colloidal form for topical application for the therapy and prophylaxis of pathological changes of the skin and/or integumentary structures of the skin and/or mucous membranes, including mucous membranes of the digestive tract, uro-genital tract and bronchial system and/or conjunctiva, containing a lipophilic phase in a quantity of 1-10% by weight, a mixture of surfactant and co-surfactant in a quantity of 1-50% by weight, a hydrophilic phase in a quantity of 40-80% by weight and, as active ingredient, cyclosporin and/or derivatives thereof in a concentration of 0.1-20% by weight.
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: October 29, 2013
    Assignee: JAGOTEC AG
    Inventors: Johannes Wohlrab, Reinhard Neubert, Konstanze Jahn
  • Patent number: 8563518
    Abstract: A composition is disclosed herein comprising from about 0.001% to about 0.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: October 22, 2013
    Assignee: Allergan, Inc.
    Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
  • Publication number: 20130266663
    Abstract: Methods for treating a condition associated with proteoglycan production in a mammal are provided. The methods comprise the administration of at least one of a calmodulin antagonist, a transient receptor potential (TRP) channel inhibitor and a calmodulin-binding peptide to the mammal.
    Type: Application
    Filed: April 29, 2011
    Publication date: October 10, 2013
    Inventors: Arthur Brown, Sandy Gian Vascotto
  • Publication number: 20130267472
    Abstract: This invention concerns an aqueous ophthalmic solution containing an immunosuppressive agent, such as cyclosporin A, and at least three polymers. The three polymers are preferably a combination of a cellulose derivative, a polyvinyl derivative, and a macrogolglycerol hydroxystearate.
    Type: Application
    Filed: March 12, 2013
    Publication date: October 10, 2013
    Applicant: LABORATOIRES THEA
    Inventors: Emmanuel Muriaux, Fabrice Mercier
  • Patent number: 8551952
    Abstract: Provided herein are methods for treatment of ocular diseases. The methods comprise administering a compound of general Formula (I): wherein R1, R2, R3, R4 and Ak are as defined in the specification.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: October 8, 2013
    Assignee: Scynexis, Inc.
    Inventor: David Renwick Houck
  • Publication number: 20130243794
    Abstract: The invention provides methods for determining the propensity to develop, or the presence of, one or more infection-induced illness(es). The invention further provides methods of treating an infection (e.g., bacterial infection), methods of diagnosing an infection-induced illness in a subject, and methods of predicting the future severity of one or more infection-induced illness(es). Also provided are kits for determining the likelihood or propensity of a subject to develop one or more infection-induced illness(es) and kits for diagnosing one or more infection-induced illness(es) in a subject and identifying a subject as having an increased risk of later developing one or more severe infection-induced illness(es).
    Type: Application
    Filed: December 5, 2011
    Publication date: September 19, 2013
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventor: Carl J. Hauser
  • Publication number: 20130244952
    Abstract: The present invention relates to a pharmaceutical composition comprising a pharmaceutical agent and a pharmaceutically acceptable carrier, which carrier comprises a protein, for example, human serum albumin and/or deferoxamine. He human serum albumin is present in an amount effective to reduce one or more side effects associated with administration of the pharmaceutical composition. The inventor also provides methods for reducing on or more side effects of administration of the pharmaceutical composition, and methods for enhancing transport and binding of a pharmaceutical agent to a cell.
    Type: Application
    Filed: October 11, 2012
    Publication date: September 19, 2013
    Applicant: Abraxis BioScience, LLC
    Inventors: Neil P. Desai, Patrick Soon-Shiong, Vuong Trieu
  • Patent number: 8536134
    Abstract: A composition comprising a therapeutically effective amount of cyclosporin A, a blend of oils having a specific gravity of from 0.90 to 1.07, and a surfactant is disclosed herein.
    Type: Grant
    Filed: February 28, 2007
    Date of Patent: September 17, 2013
    Assignee: Allergan, Inc.
    Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
  • Patent number: 8524671
    Abstract: The present invention provides a method for the treatment of inflammatory diseases and/or conditions, e.g. allergic conjunctivitis, uveitis or phacoanaphylactic endophthalmitis in an eye of a mammal, said method comprising administering to said mammal in need of treatment a therapeutically effective amount of a novel cyclosporin A derivative selected from the group consisting of compounds represented by the formula: wherein R1 is S-Alk-R wherein Alk is an alkylene linkage, preferably a methylene or poly methylene linkage, or a polyalkenylene linkage, e.g. a C3 to C6 alkenylenyl linkage and R is a hydrogen or a unsubstituted or substituted hydrocarbyl group.
    Type: Grant
    Filed: May 21, 2010
    Date of Patent: September 3, 2013
    Assignee: Allergan, Inc
    Inventors: Michael E. Garst, Michael E. Stern
  • Publication number: 20130224151
    Abstract: The present disclosure relates to methods of using fatty acid amide hydrolase (FAAH) inhibitors alone or in combination for the treatment or prevention of abdominal, visceral or pelvic pain. Also described herein are pharmaceutical compositions comprising a FAAH inhibitor, alone or in combination with an additional therapeutic agent for the treatment of abdominal, visceral or pelvic pain.
    Type: Application
    Filed: March 31, 2011
    Publication date: August 29, 2013
    Applicants: UNITED STATES OF AMERICA, IRONWOOD PHARMACEUTICALS, INC
    Inventors: James Philip Pearson, Mark G. Currie, Yvette Tache, Muriel Larauche
  • Publication number: 20130210704
    Abstract: The present invention relates to a compound of the Formula (I)): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, and hair loss.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 15, 2013
    Applicant: S&T GLOBAL INC.
    Inventor: S&T Global Inc.
  • Patent number: 8501174
    Abstract: Therapeutic methods are disclosed herein.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: August 6, 2013
    Assignee: Allergan, Inc.
    Inventors: Gregg Feinerman, Neil Barth, Rhett M. Schiffman, Pamela S. Barnett
  • Publication number: 20130195769
    Abstract: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition.
    Type: Application
    Filed: March 11, 2013
    Publication date: August 1, 2013
    Applicant: FOAMIX LTD.
    Inventor: Foamix Ltd.
  • Publication number: 20130190252
    Abstract: The present invention relates to an improved pharmaceutical composition and in particular to a pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of a lipophilic active ingredient with milk as a solubilizing/dispersing agent and methods for the preparation thereof.
    Type: Application
    Filed: March 6, 2013
    Publication date: July 25, 2013
    Applicant: PHARMATHEN S.A.
    Inventor: PANAYOTIS MACHERAS
  • Publication number: 20130190223
    Abstract: The compounds of the present invention are non-immunosupressive cyclosporine analogue molecules that are able to bind cyclophilin. Said compounds include a modified side chain of amino acid I of cyclosporin A, consisting of an oxyalkyl having substituents R?, R1 and R2, where R? is H or Acetyl; R1 is a saturated or unsaturated straight chain or branched aliphatic carbon chain; and R2 may be a hydrogen; a unsubstituted, N substituted or NN disubstituted amide; a N substituted or unsubstituted acyl protected amine; a carboxylic acid; a N substituted or unsubstituted amine; a nitrile; a ester; a ketone; a hydroxy, dihydroxy, trihydroxy or polyhydroxy alkyl; or a substituted or unsubstituted aryl.
    Type: Application
    Filed: July 3, 2009
    Publication date: July 25, 2013
    Applicant: ISOTECHNIKA PHARMA INC.
    Inventors: Alexander Hegmans, Bruce W. Fenske, David P. Czajkowski, Darren R. Ure, Shin Sugiyama, Dan J. Trepanier, David H. McGlade, Mark D. Abel
  • Publication number: 20130189246
    Abstract: Provided are compositions and methods for treatment of ophthalmic conditions, such as retinal detachment and age-related macular degeneration. Various fluorenone derivatives described herein can stimulate fluid removal from the subretinal space and down-regulate reactive gliosis. Administration of compounds described herein can provide an alternative or an adjunct to an invasive procedure to reattach the retina.
    Type: Application
    Filed: November 5, 2010
    Publication date: July 25, 2013
    Applicant: The Trustees of Columbia University in the City of New York
    Inventor: Konstantin Petrukhin
  • Publication number: 20130183267
    Abstract: The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
    Type: Application
    Filed: January 4, 2013
    Publication date: July 18, 2013
    Applicant: Enanta Pharmaceuticals, Inc.
    Inventor: Enanta Pharmaceuticals, Inc.
  • Publication number: 20130177609
    Abstract: An ophthalmic composition comprises an ophthalmic drug that has a low solubility in water and a surfactant, wherein the ophthalmic drug is present at a concentration from about 3 to about 7000 times the solubility of the drug in water. A volume of about 1-15 microliter is administered topically to an eye of a subject to treat or control a condition for which the drug is effective.
    Type: Application
    Filed: February 27, 2013
    Publication date: July 11, 2013
    Inventor: Bausch & Lomb Incorporated
  • Publication number: 20130177626
    Abstract: The invention relates to liquid pharmaceutical compositions containing: a) a therapeutically effective dose of a cyclosporin; b) an aqueous carrier liquid; c) a first solubilizing substance selected among the group of phospholipids; and d) a second solubilizing substance selected among the group of non-ionic surfactants. Preferably, the cyclosporin is liposome solubilized. The inventive composition is suitable for oral, parenteral, nasal, mucosal, topical, and particularly pulmonary application in the form of an aerosol.
    Type: Application
    Filed: December 4, 2012
    Publication date: July 11, 2013
    Applicant: PARI PHARMA GMBH
    Inventor: PARI Pharma GmbH
  • Publication number: 20130172268
    Abstract: An embodiment is a medical prosthesis for blocking or reducing tear flow through a punctum or canaliculus of a human eye and delivering a drug to the eye that comprises a dehydrated covalently crosslinked synthetic hydrophilic polymer hydrogel with dimensions to pass through a puncta lacrimali, with the dehydrated hydrogel absorbing physiological water to swell to at least 1 mm in cross-sectional width and conformably fit a canaliculus, with the hydrogel comprising a therapeutic agent dispersed through the hydrogel for release to an eye, with the hydrogel having a water content of at least about 50% by weight or volume when allowed to fully hydrate in vitro in physiological saline.
    Type: Application
    Filed: February 26, 2013
    Publication date: July 4, 2013
    Applicant: INCEPT, LLC
    Inventor: Incept, LLC
  • Publication number: 20130171268
    Abstract: The present invention relates to compositions and methods for prophylactic and/or therapeutic treatment of conditions related to mitochondrial function. In various aspects, the present invention comprises administering one or more compounds selected from the group consisting of epicatechin, an epicatechin derivative, catechin, a catechin derivative, nicorandil, and a nicorandil derivative in an amount effective to ameliorate mitochondrial toxicity caused by administration of a chemical, food, or drug.
    Type: Application
    Filed: June 5, 2012
    Publication date: July 4, 2013
    Inventors: Francisco Villarreal, Alan Maisel, George Schreiner, Guillermo M. Ceballos Reyes, Pam Taub
  • Patent number: 8470784
    Abstract: The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Grant
    Filed: August 23, 2010
    Date of Patent: June 25, 2013
    Assignee: Stealth Peptides International, Inc.
    Inventors: Liping Liu, Shibo Tang, Xiaoling Liang
  • Publication number: 20130150311
    Abstract: In one aspect, the present invention is directed to a dry, flowable and compressible composition, useful as a pharmaceutical excipient, which composition comprises a mixture of hydrophobic and hydrophilic poly(ethylene oxide)-polypropylene oxide)-poly(ethylene oxide) block copolymers, and which possesses a Carr index of less than about 20. In other aspects, the present invention is directed a pharmaceutical composition comprising such adjuvant and a pharmaceutically active ingredient; as well as to a method of making the compositions.
    Type: Application
    Filed: December 13, 2011
    Publication date: June 13, 2013
    Inventors: Grzegorz Pietrzynski, Valery Alakhov, Kishore Patel
  • Publication number: 20130142807
    Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
    Type: Application
    Filed: January 25, 2013
    Publication date: June 6, 2013
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventor: Rigel Pharmaceuticals, Inc.
  • Patent number: 8450281
    Abstract: The present invention relates to the use of a nonimmunosuppressive cyclosporin A derivative for reducing mitochondrial dysfunction and the rate of apoptosis of muscle cells of patients diagnosed with Ullrich congenital muscular dystrophy or Bethlem myopathy.
    Type: Grant
    Filed: January 3, 2008
    Date of Patent: May 28, 2013
    Assignee: Debiopharm S.A.
    Inventors: Paolo Bernardi, Gregoire Vuagniaux, Rafael Crabbe
  • Publication number: 20130123195
    Abstract: Disclosed herein are methods of treating diseases of the eye by administering to the subconjunctival space a formulation comprising cyclosporin A form 2 and a hydrogel.
    Type: Application
    Filed: November 14, 2012
    Publication date: May 16, 2013
    Applicant: ALLERGAN, INC.
    Inventor: ALLERGAN, INC.
  • Publication number: 20130123193
    Abstract: Disclosed herein are methods of making cyclosporin A Form 2.
    Type: Application
    Filed: November 14, 2012
    Publication date: May 16, 2013
    Applicant: ALLERGAN, INC.
    Inventors: Ke Wu, Scott W. Smith
  • Publication number: 20130122059
    Abstract: Disclosed herein are methods of formulating cyclosporin A Form 2.
    Type: Application
    Filed: November 14, 2012
    Publication date: May 16, 2013
    Applicant: ALLERGAN, INC.
    Inventors: Anuradha Gore, Prem Swaroop Mohanty, E. Quinn Farnes
  • Publication number: 20130123194
    Abstract: Disclosed herein are autoclavable formulations of cyclosporin A Form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations.
    Type: Application
    Filed: November 14, 2012
    Publication date: May 16, 2013
    Applicant: ALLERGAN, INC.
    Inventors: Wendy M. Blanda, Hongwen M. Rivers, David A. Marsh, Michelle Luu
  • Patent number: 8435520
    Abstract: A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute rejection, reducing early graft damage, improving early xenograft function and promoting long term survival of said transgenic xenografts comprising the steps of i) contacting the body fluid removed from a human recipient with a xenoantigenic material which is bound to a biocompatible solid support, ii) reintroducing the treated body fluid into the recipient, and iii) treating the recipient with said pharmaceutical composition.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: May 7, 2013
    Inventors: Hendrik J. Schuurman, Emanuele Luigi Maria Cozzi, Francoise Richard, Guy Taccard, David James Graham White, Peter John Friend, John Wallwork, Paolo Brenner
  • Publication number: 20130109630
    Abstract: This document features method related to variants in the Inverted Formin 2 (INF2) gene that are susceptibility to focal segmental glomerulosclerosis (FSGS). For example, methods of using such variants for risk assessment and for diagnosing and optimizing treatment of FSGS are provided.
    Type: Application
    Filed: December 7, 2010
    Publication date: May 2, 2013
    Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Martin Pollak, Elizabeth J. Brown, Johannes Schlondorff
  • Publication number: 20130108573
    Abstract: Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 26, 2012
    Publication date: May 2, 2013
    Applicant: Lumena Pharmaceuticals, Inc.
    Inventor: Lumena Pharmaceuticals, Inc.
  • Publication number: 20130108689
    Abstract: A hydrophobic drug delivery system that includes a plant derived sterol (stanol) or a sterol (stanol) derived ester, an emulsifier and an active, hydrophobic drug, all dissolved and then dried to form a liposome delivery system.
    Type: Application
    Filed: December 17, 2012
    Publication date: May 2, 2013
    Applicant: ZOMANEX, LLC
    Inventor: Zomanex, LLC
  • Patent number: 8431538
    Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, traumatic brain injury, stroke, malaria, an autoimmune disease, autism, and inflammation, also are disclosed.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: April 30, 2013
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Alan Kozikowski, Kyle V. Butler, Jay H. Kalin
  • Publication number: 20130101658
    Abstract: A drug insert is configured for use with an implant. The implant is configured for insertion into a lacrimal canaliculus. The drug insert includes a drug core comprising a therapeutic agent and a polymer; and a sheath body comprising material substantially impermeable to the therapeutic agent, wherein the drug core is positioned within the sheath body. The sheath body is configured to provide an exposed end of the drug core that releases therapeutic agent to an eye when the drug insert is disposed within the implant and the implant is positioned in the lacrimal canaliculus. A distal end of the drug core is sealed with a medical-grade adhesive.
    Type: Application
    Filed: October 4, 2012
    Publication date: April 25, 2013
    Applicant: QLT INC.
    Inventor: QLT INC.
  • Publication number: 20130101615
    Abstract: This invention is a method for immunizing, preventing or treating a Mycobacterium avium subspecies paratuberculosis-associated disease or condition by screening subjects for markers indicative of predisposition or susceptibility to a Mycobacterium avium subspecies paratuberculosis-associated disease or condition and administering a Mycobacterium avium subspecies paratuberculosis vaccine or prophylactic or therapeutic agent.
    Type: Application
    Filed: December 14, 2012
    Publication date: April 25, 2013
    Inventor: Robert J. Greenstein
  • Publication number: 20130096069
    Abstract: This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including into and across ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.
    Type: Application
    Filed: September 10, 2012
    Publication date: April 18, 2013
    Inventors: Jonathan B. Rothbard, Paul A. Wender, P. Leo McGrane, Lalitha V.S. Sista, Thorsten A. Kirschberg
  • Patent number: 8420604
    Abstract: Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.
    Type: Grant
    Filed: June 14, 2010
    Date of Patent: April 16, 2013
    Assignee: Mannkind Corporation
    Inventors: Mark Hokenson, Keith A. Oberg
  • Publication number: 20130089512
    Abstract: New heteroaryl imidazolone derivatives having the chemical structure of formula (I) are disclosed, as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).
    Type: Application
    Filed: June 14, 2011
    Publication date: April 11, 2013
    Inventors: Paul Robert Eastwood, Jacob Gonzalez Rodriguez, Elena Gomez Castillo, Jordi Bach Taña
  • Publication number: 20130059795
    Abstract: This invention describes a novel composition of matter describing a complex comprising leaf protein and a lipophilic substance(s), along with the method of producing it. Delivery of lipid-soluble materials into the body is challenging because they are generally highly insoluble in water and very subject to oxidative degradation. The inventors have found that leaf protein—the water-soluble proteins derived from plant leaves—can efficiently form a complex with lipophilic materials. This leaf protein—lipid-soluble material complex is an effective carrier of lipophilic substances. As such, the leaf protein—lipid-soluble material complex disclosed herein can be used for the delivery of lipophilic vitamins, fatty acids, caretenoids, lipophilic drugs, and other lipophilic materials. This complex can be used to deliver lipophiles in foods, nutritional and dietary supplements, topical compositions and in pharmaceutical products.
    Type: Application
    Filed: March 7, 2011
    Publication date: March 7, 2013
    Inventors: Yangming Martin Lo, Ansu Elizabeth Cherian, Neil Allen Belson
  • Publication number: 20130059796
    Abstract: Cyclosporin A compositions are disclosed herein comprising an oil and a surfactant. These are useful in the treatment of dry eye disease.
    Type: Application
    Filed: October 11, 2012
    Publication date: March 7, 2013
    Applicant: ALLERGAN, INC
    Inventor: Allergan, Inc.
  • Publication number: 20130040895
    Abstract: Biodegradable drug delivery systems suitable for injection into an ocular region or site and methods for treating ocular conditions. The drug delivery systems provide increased drug residency time and attendant therapeutic benefit.
    Type: Application
    Filed: October 16, 2012
    Publication date: February 14, 2013
    Applicant: ALLERGAN, INC
    Inventor: ALLERGAN, INC
  • Patent number: 8367097
    Abstract: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; non-dispersed mass-forming liquid formulations which form a gel or gel-like substance in an aqueous medium; liquid formulations, comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: February 5, 2013
    Assignee: Santen Pharmaceutical Co., Ltd.
    Inventors: Sreenivasu Mudumba, Philippe J M Dor, Thierry Nivaggioli, David A. Weber, Sidiq Farooq
  • Patent number: 8367618
    Abstract: The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
    Type: Grant
    Filed: January 30, 2010
    Date of Patent: February 5, 2013
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Guoqiang Wang, Jiang Long, Xuri Gao
  • Publication number: 20130029919
    Abstract: Ophthalmic products and related methods are described herein. These methods include a stabilizing composition comprising a therapeutically active agent which is separated from a liquid vehicle composition by a barrier. The barrier may be removed to allow the two compositions to mix to provide an ophthalmically acceptable liquid comprising the therapeutically active agent.
    Type: Application
    Filed: July 25, 2012
    Publication date: January 31, 2013
    Applicant: ALLERGAN, INC.
    Inventors: Anuradha V. GORE, Sai M. SHANKAR, Sukhon LIKITLERSUANG, Chetan P. PUJARA, Sesha NEERVANNAN
  • Publication number: 20130023482
    Abstract: The present invention relates generally to crystalline forms of cyclosporine A and particularly to a newly identified form of cyclosporine A. The invention further relates to methods for its preparation and to methods for treating certain ocular disorders.
    Type: Application
    Filed: May 25, 2012
    Publication date: January 24, 2013
    Inventors: Anuradha V. Gore, Kiomars Karami, Ke Wu, Richard S. Graham, Scott W. Smith
  • Patent number: 8357660
    Abstract: Methods are provided for inhibiting growth of prolactin-responsive cancer cells and treating prolactin-responsive malignancies via administration an agent such as cyclosporine A which directly inhibits an enzymatic activity of a cyclophilin.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: January 22, 2013
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Charles V. Clevenger